Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans

Journal of Clinical Investigation

Volumn 121, Issue 4, 2011, Pages 1574-1584

  Lin, Yun ^a,b   Zhang, Li ^a,b,c   Cai, Ann X ^a   Lee, Mark ^d   Zhang, Wandi ^a   Neuberg, Donna ^b   Canning, Christine M ^a,b,e   Soiffer, Robert J ^b,e   Alyea, Edwin P ^b,e   Ritz, Jerome ^a,b,e   Hacohen, Nir ^d   Means, Terry K ^d   Wu, Catherine J ^a,b,e  

^a Cancer Vaccine Center   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SICHUAN UNIVERSITY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FC RECEPTOR IIA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMATINIB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NUCLEIC ACID; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; UPREGULATION;

ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL3; CHEMOKINE CXCL10; FEMALE; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; NUCLEIC ACIDS; TISSUE DONORS; TOLL-LIKE RECEPTORS; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; YOUNG ADULT;

EID: 79953328962     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44581     Document Type: Article

References (56)

1. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006;90:133-173. (Pubitemid 43765800)
2. Lampert IA, Moore RH, Huby R, Cohen J. Observations on the role of endotoxin in graft-versus-host disease. Prog Clin Biol Res. 1988;272:351-359.
3. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987-995. (Pubitemid 41057715)
4. Savarese E, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008;58(4):1107-1115. (Pubitemid 351564013)
5. Kelly-Scumpia KM, et al. In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen. Arthritis Rheum. 2007;56(10):3379-3386.
6. Groom JR, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 2007;204(8):1959-1971. (Pubitemid 47236330)
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823-835. (Pubitemid 44631651)
8. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25(3):417-428. (Pubitemid 44354217)
9. Lau CM, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202(9):1171-1177. (Pubitemid 41586947)
10. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115(2):407-417. (Pubitemid 40385482)
11. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity. 2008;29(2):249-260.
12. Vollmer J. CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006;25(3-4):125-134. (Pubitemid 44034577)
13. Vollmer J, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004;48(6):2314-2317. (Pubitemid 38691640)
14. Kolb HJ, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
15. Alyea EP, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91(10):3671-3680. (Pubitemid 28225734)
16. Wu CJ, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000;106(5):705-714.
17. Zhang W, et al. Graft-versus-leukemia antigen CML66 elicits coordinated B and T cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010;16(10):2729-2739.
18. Latz E, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190-198. (Pubitemid 38208361)
19. Wu CJ, et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005;11(12):4504-4511. (Pubitemid 40825641)
20. Biernacki MA, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010;70(3):906-915.
21. Wang Q, et al. RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Lett. 2008;269(1):127-138.
22. Yang XF, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001;98(13):7492-7497.
23. Amit I, et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science. 2009;326(5950):257-263.
24. Huang Q, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294(5543):870-875. (Pubitemid 33032108)
25. McGettrick AF, O'Neill LA. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol. 2007;139(2):185-193. (Pubitemid 47493098)
26. Durakovic N, et al. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007;109(10):4564-4574. (Pubitemid 46743428)
27. Taylor PA, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008;112(8):3508-3516.
28. Chakraverty R, et al. The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells. J Immunol. 2008;181(10):6820-6828.
29. She K, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(4):386-397. (Pubitemid 46421893)
30. Datta SK, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol. 2003;170(8):4102-4110. (Pubitemid 36428173)
31. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol. 2004;172(3):1501- 1507. (Pubitemid 38116793)
32. Maurer T, et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol. 2002;32(8):2356-2364. (Pubitemid 34965899)
33. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033-1036. (Pubitemid 36222922)
34. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004;21(5):733-741. (Pubitemid 39487894)
35. Schwarz K, et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol. 2003;33(6):1465-1470. (Pubitemid 36790406)
36. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 2005;438(7066):364-368. (Pubitemid 41643953)
37. Goforth R, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2009;58(4):517-530.
38. Barr TA, Brown S, Ryan G, Zhao J, Gray D. TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007;37(11):3040-3053. (Pubitemid 350131284)
39. Ketloy C, et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol. 2008;125(1-2):18-30.
40. Singh NJ, Cox M, Schwartz RH. TLR ligands differentially modulate T cell responses to acute and chronic antigen presentation. J Immunol. 2007;179(12):7999-8008.
41. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18(1):65-73. (Pubitemid 29411092)
42. Fournie GJ, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 1995;91(2):221-227.
43. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646-650. (Pubitemid 8051621)
44. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89-97. (Pubitemid 28293013)
45. Tesniere A, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20(5):504-511.
46. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991-2001.
47. Aliyari R, Ding SW. RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol Rev. 2009;227(1):176-188.
48. Takeshita F, Ishii KJ. Intracellular DNA sensors in immunity. Curr Opin Immunol. 2008;20(4):383-388.
49. Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev. 2009;227(1):54-65.
50. Marina O, et al. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010;70(4):1344-1355.
51. Rozkova D, et al. Toll-like receptors on B-CLL cells: Expression and functional consequences of their stimulation. Int J Cancer. 2010;126(5):1132- 1143.
52. Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR, Alkan SS. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol. 2007;7(8):1111-1121.
53. Zheng R, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res. 2008;68(11):4045-4049.
54. Joachimiak MP, Weisman JL, May B. JColorGrid: software for the visualization of biological measurements. BMC Bioinformatics. 2006;7:225.
55. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 2000;96(5):1857-1864. (Pubitemid 30661071)
56. Geiss GK, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325. (Pubitemid 351355126)